Get GeriPal Email Updates

Search This Blog

SPRINT Trial: Should We Aim for Lower Target Blood Pressures for Older Adults?

The SPRINT trial came out about 6 months ago – it was supposed to revolutionize the way we thought about treating older adults with hypertension. “But adding *more* medicines goes against everything I believe in!” you say. Those are my feelings too, though it’s important to consider what the evidence actually shows.

Let’s break down the SPRINT trial to examine what they did, what they found, and whether it applies to the geriatric patients we care for.

But wait, don’t we already know the best blood pressure targets?

It depends on who you talk to.

Let’s look at the data we have so far: the Systolic Hypertension in the Elderly Program (SHEP) and the Hypertension in the Very Elderly Trial (HYVET) showed BP less than 150mg is beneficial. Observational studies show the lower you go, down to 115/75, the more you can prevent cardiovascular outcomes…but the observational studies don’t always show the other side: adverse effects. Really lowering blood pressure that low requires lots of medications – a cost in term of possible side effects (falls, orthostatic hypotension) and actual monetary costs.

There is data from randomized controlled trials as well: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure trial compared intensive blood pressure control with a goal of less than 140 to less than 120; very similar to SPRINT, but in a diabetic population. The ACCORD trial did not demonstrate a clear benefit for treatment to the lower target for on it’s primary composite cardiovascular disease outcome (Hazard Ratio 0.88, 95% CI: 0.73 to 1.06, P =0.20).

As a result, experts -cardiologist, nephrologists, geriatricians- differ on their thoughts on what the best goal blood pressure for older adults is; this study set out to answer that question.
What did the SPRINT trial do?

SPRINT was randomized, controlled trial that compared the benefit of treating of systolic blood pressure, with a goal of less than 120 mmHg to a goal of less than 140 mmHg, in in non-diabetic patients who were over 50 years old at an increased risk of cardiovascular events. Increased risk of cardiovascular events was defined as: “clinical or subclinical
cardiovascular disease other than stroke, CKD with eGFR of 20-60, 10-year risk of cardiovascular disease of ≥ 15% Framingham, or age over 75 years old.

The primary outcome was rate of the composite outcome of myocardial infarction,
acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes. This composite outcome maximizes power in the study, and consistent with other major cardiovascular trials; in fact it is same primary outcome as the ACCORD trial mentioned above.

They excluded those who had diabetes or stroke, those who had low blood pressure (systolic less than 110) after 1 min of standing, and anyone in a nursing home, only community dwelling patients were included in the trial. SPRINT also excluded people who they thought couldn’t adhere to the treatments or attend the necessary study visits.
What did they find?

There were 9,361 participants in the study, and 2,636 of them were >75yrs old! Overall 35% were woman, and the average BMI was 29. The mean baseline blood pressure was 139mmHg, and 90% of patients were on antihypertensive medications to start with.

The blood pressure lowering worked, but required more medications: Mean blood pressure in intensive group was 121.5/ 68.7 mmHg; the mean number of medications was 2.8. The mean blood pressure in standard treatment group was 134.6/ 76.3 mmHg; the mean number of medications was 1.8.

The main outcome (combined MI, stroke, CHF, CV death) happened in 243 (1.65% per year) in the intensive-treatment group, and 319 (2.19% per year) in the standard-treatment group.

Said another way, the Hazard Ratio for intensive treatment was 0.75 [95% CI 0.64 to 0.89]

The number needed to treat (NNT) to prevent one primary outcome event (combined MI, stroke, CHF, CV death), was 61 over ~3 yrs. This is impressive! CV death and all cause mortality was also reduced, NNT of 86 and 167 respectively, over 3.2 yrs.

Serious adverse events occurred in 1,793 participants in the intensive-treatment group (38.3%) and in 1,736 participants in the standard-treatment group (37.1%).

Serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or acute renal failure, occurred more frequently in the intensive treatment group. There was no difference in injurious falls or bradycardia, and actually less orthostatic hypotension in the intensive treatment group.

Can I trust these study results?

This was a well done study. They study was stopped early (after 3.26 years of the planned 5 years). In small trials this can introduce bias or exaggerate the findings, however SPRINT is large with trial with the large number of primary end points (n=564), so results are likely valid. It was open-label, so participants and investigators knew treatment assignment. Non-blinded participants/doctors could perhaps introduce some systematic bias, though hard to see how would influence results either way, and I would not discount study results based on this.

The $1 million dollar question - does this apply to the patients we care for? Two issues here: the generalizability of the study and adverse events.

Generalizability

I think that if you took one of my geriatric clinic patients who fit the study criteria and study protocol, the study results might apply to them. This might be a 83 yo gentleman with mild CKD and hypertension, relatively healthy and active, able to manage his own meds and come to clinic for regular blood pressure checks.

Blood pressure was measured in this study as the average of 3 measurements over 5 min, taken automatically without a doctor in the room. In a separate article, the SPRINT authors note that the average blood pressure measurement could be much lower than a single blood taken by a doctor wearing white coat. This could lead to overtreatment if the just one blood pressure from clinic was used to adjust medications.

In addition, blood pressure was monitored and meds were adjusted each month – adding *and subtracting * meds to keep at goal. This much more intensive blood pressure management than is typical done in many clinics.

It is also important to remember who was excluded from SPRINT. First, no nursing home patients were included. In addition, wee can’t tell from the baseline characteristics that were reported about the participants’ level of frailty, functional status, gait speed, or ADL dependence. So I would be nervous generalizing to a frail older geriatric population, who might be very different than participants included in this study.

Adverse Events
The adverse events are very important to consider in our geriatric patients, especially syncope and hypotension! There was no difference in rates of falls (I am not sure what to make of this- maybe this was captured by syncope?). It is also important to note that randomized controlled trials are not designed to pick up all adverse events well. Even though this was large trial, more side effects could come out in observational studies/ clinical practice, and there could be more frequent adverse events when intensive blood pressure treatment is applied to real life.

My take-away:

This was a VERY well done study. The number needed to treat of 61 over 3 years is impressive. However, in our geriatric population, we have to compare the benefits to harms of syncope, hypotension (and resultant hip fractures?), and potential overtreatment due to white coat HTN. In the geriatric population, it is also important to consider the time to benefit, and incorporate life expectancy, co-morbid conditions, risks of polypharmacy, and patient values and desire to take more medications.

Based on this trial, are you going to target a lower blood pressure for some of your patients? If so, which ones? How would you explain it to them?

Get link

Facebook

Twitter

Pinterest

Email

Other Apps

Get link

Facebook

Twitter

Pinterest

Email

Other Apps

Comments

In June of 2015, it was discovered that I had type 2 diabetes. By the end of the month, June 26th to be exact, I was given a prescription for Metformin. Under the direction of my doctor, I stated the ADA diet and followed it completely for several weeks but was unable to get my blood sugar below 140. With no results to how for my hard work, I panicked and called my doctor. His response? Deal with it. With was then that I began to feel that something wasn’t right and began to do my own research. It was through that research that I found Rachel’s blog http://www.myhealthlives.com . I read it from cover to cover that same day. That day, I started the diet and by the next morning, my blood sugar was 100. The next day, it read in the 90s for the first time since I was diagnosed. Since then, I have a fasting reading between the mid 70s and 80s. My doctor was so surprised at the results that, the next week, he took me off the Metformin. Then I lost 30 pounds in the first month. Since that first day, I have lost more than 6 inches off my waist because I’m able to work out twice a day while still having lots of energy. GOOD

Acknowledging the quality of the study as remarkably powered to resolve the impact of moving target blood pressure downward 20 mmHg, such science drives me crazy! If my exam room was big enough to accomodate a population of 9,361 people desperately longing to reduce the risk of stroke, heart attack, CHF, or sudden death by ONE PERCENT PER YEAR, I might care. And if this population stuffed into my exam room was so incredibly civic minded as to embrace the fact that their participation has a ONE IN 243 chance of helping THEM personally, I might care.

I don't care because the individuals I see every day have significantly different concerns like who will care for them as they lose the ability to care for themselves. Like how to get to the dozens of appointments we schedule them for or how to pay for their 2.8 antihypertensives, and 4.2 other medications, not to mention how to afford quality food. They also seem to value the effort to make sense out of their very nature, the meaning of their lives and the grief and loss that accompanies the completion of one's life.

Popular posts from this blog

My colleagues often ask me: “Why are Chinese patients so resistant to hospice and palliative care?” “Why are they so unrealistic?” “Don’t they understand that death is part of life?” “Is it true that with Chinese patients you cannot discuss advance directives?”

As a Chinese speaking geriatrician and palliative care physician practicing in Flushing, NY, I have cared for countless Chinese patients with serious illnesses or at end of life. Invariably, when Chinese patients or families see me, they ask me if I speak Chinese. When I reply “I do” in Mandarin, the relief and instant trust I see on their faces make my day meaningful and worthwhile.

At my hospital, the patient population is about 30% Asian, with the majority of these being Chinese. Most of these patients require language interpretation. It becomes an interesting challenge and opportunity, as we often need to discuss advance directives, goals of care, and end of life care options…

In this week's GeriPal podcast we discuss delirium, with a focus on prevention. We are joined by internationally acclaimed delirium researcher Sharon Inouye, MD, MPH. Dr Inouye is Professor of Medicine at Harvard Medical School and Director of the Aging Brain Center in the Institute for Aging Research at Hebrew SeniorLife.

Dr. Inouye's research focuses on delirium and functional decline in hospitalized older patients, resulting in more than 200 peer-reviewed original articles to date. She has developed and validated a widely used tool to identify delirium called the Confusion Assessment Method (CAM), and she founded the Hospital Elder Life Program (HELP) to prevent delirium in hospitalized patients.

We are also joined by guest host Lindsey Haddock, MD, a geriatrics fellow at UCSF who asks a great question about how to implement a HELP program, or aspects of the program, in a hospital with limited resources.

Estimating prognosis is hard and clinicians get very little training on how to do it. Maybe that is one of the reasons that clinicians are more likely to be optimistic and tend to overestimate patient survival by a factor of between 3 and 5. The question is, aren't we better as palliative care clinicians than others in estimating prognosis? This is part of our training and we do it daily. We got to be better, right?

Big findings from this JPSM paper include that we, like all other clinicians, are an optimistic bunch and that it actually does impact outcomes. In particular, the people whose survival was overestimated by a palliative care c…

GeriPal (Geriatrics and Palliative care) is a forum for discourse, recent news and research, and freethinking commentary. Our objectives are: 1) to create an online community of interdisciplinary providers interested in geriatrics or palliative care; 2) to provide an open forum for the exchange of ideas and disruptive commentary that changes clinical practice and health care policy; and 3) to change the world.

No confidential patient information should be placed on GeriPal, nor should any confidential information be placed in the comments. The information provided on GeriPal is designed to complement, not replace, the relationship between a patient and and his/her own medical providers. The editors (Alex Smith and Eric Widera) reserve the right to remove comments that are deemed inappropriate due to the commercial, abusive, or offensive nature of a comment. If you think your comment was deleted for inappropriate reasons, please email either Alex or Eric.

GeriPal's mission is to improve the disemination of information in both geriatics and palliative medicine. GeriPal was created with the support of the Division of Geriatrics at the University of California San Francisco. Its content though is strictly the work of its authors and has no affiliation with or support from any organization or institution. All opinions expressed on this website are solely those of its authors & do not reflect the opinions of any academic institution or medical center. This web site does not accept advertisements. All email addresses collected by GeriPal for feed distribution will be kept confidential and will never be used for commercial reasons. If you reproduce the material on the website please cite appropriately. For questions regarding the site please email Alex Smith, MD (aksmith@ucsf.edu) or Eric Widera, MD (eric.widera@ucsf.edu)